To identify and describe long-term quality of life (QOL) issues in patients with metastatic melanoma treated with checkpoint inhibitors who achieved cancer control for a minimum of 12 months and remain on maintenance checkpoint inhibitor therapy.

Inclusion Criteria:

• Be able to speak and read English
• Be able to provide informed consent
• Have been diagnosed with metastatic melanoma at age 18 years or older
• Have been treated with either single agent or combination checkpoint inhibitor
• Be at least 12 months since first dose of above named agents
• Received no other systemic therapy after initiation of immunotherapy (interval radiation or surgery will be permitted based on review with primary treating medical oncologist)

Exclusion Criteria:

• Patients with cognitive, visual, or motor impairment such that they cannot complete the survey as assessed by the research or clinical team

• Patients who developed a subsequent cancer after starting on checkpoint inhibitor(s), exclusive of non-melanoma superficial skin cancers

• Patients with clinical documentation of progressive disease on the most recent assessment in the electronic medical record

• Patients with symptomatic progression but continue on immunotherapy

  • Note: For any patients where the disease status is not clear, we will confirm that the disease is either stable or responsive with their primary treating medical oncologist

The melanoma service has agreed to provide this research team with access to a list of patients who are potentially eligible for this survey.